Minerva Neurosciences (NERV) Competitors $2.29 +0.10 (+4.57%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends NERV vs. BYSI, VNRX, ATRA, CNTB, SPRO, MURA, IVVD, AADI, KRON, and IMMXShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include BeyondSpring (BYSI), VolitionRx (VNRX), Atara Biotherapeutics (ATRA), Connect Biopharma (CNTB), Spero Therapeutics (SPRO), Mural Oncology (MURA), Invivyd (IVVD), Aadi Bioscience (AADI), Kronos Bio (KRON), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. BeyondSpring VolitionRx Atara Biotherapeutics Connect Biopharma Spero Therapeutics Mural Oncology Invivyd Aadi Bioscience Kronos Bio Immix Biopharma Minerva Neurosciences (NASDAQ:NERV) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is NERV or BYSI more profitable? Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% BeyondSpring N/A N/A N/A Do institutionals and insiders believe in NERV or BYSI? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, NERV or BYSI? Minerva Neurosciences has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Do analysts rate NERV or BYSI? Minerva Neurosciences presently has a consensus target price of $5.00, indicating a potential upside of 118.34%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Minerva Neurosciences is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, NERV or BYSI? BeyondSpring has higher revenue and earnings than Minerva Neurosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M-$0.44-5.20BeyondSpring$1.88M33.91-$21.03MN/AN/A Does the media refer more to NERV or BYSI? In the previous week, Minerva Neurosciences had 2 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Minerva Neurosciences and 0 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Minerva Neurosciences' score of 0.96 indicating that BeyondSpring is being referred to more favorably in the news media. Company Overall Sentiment Minerva Neurosciences Positive BeyondSpring Very Positive Does the MarketBeat Community favor NERV or BYSI? Minerva Neurosciences received 162 more outperform votes than BeyondSpring when rated by MarketBeat users. However, 66.79% of users gave BeyondSpring an outperform vote while only 57.74% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34757.74% Underperform Votes25442.26% BeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% SummaryBeyondSpring beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.01M$6.82B$5.12B$9.29BDividend YieldN/A3.06%4.74%4.06%P/E Ratio-5.2010.41133.8817.48Price / SalesN/A283.281,252.63139.75Price / CashN/A56.6540.4137.96Price / Book-0.565.434.904.91Net Income-$30M$150.36M$117.59M$224.90M7 Day Performance-2.55%-5.32%14.51%-1.39%1 Month Performance4.09%0.49%17.46%5.43%1 Year Performance-64.50%16.20%35.87%22.89% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences4.0429 of 5 stars$2.29+4.6%$5.00+118.3%-65.9%$16.01MN/A-5.209Gap UpBYSIBeyondSpringN/A$1.60-2.7%N/A+61.6%$62.25M$1.88M0.0080Positive NewsGap DownVNRXVolitionRx2.0885 of 5 stars$0.67+18.6%$3.75+459.7%-18.2%$62.09M$770,000.00-1.5780Analyst ForecastATRAAtara Biotherapeutics3.8822 of 5 stars$10.59+2.5%$16.67+57.4%-29.9%$61.00M$100.44M-0.40165CNTBConnect Biopharma3.6536 of 5 stars$1.08-3.4%$8.00+640.7%+15.5%$59.68M$24.12M0.00110Short Interest ↓News CoveragePositive NewsGap DownSPROSpero Therapeutics4.6683 of 5 stars$1.09+1.9%$5.00+358.7%-17.1%$59.43M$103.78M15.2946Positive NewsGap UpMURAMural Oncology3.3569 of 5 stars$3.45-5.2%$16.00+363.8%+0.3%$58.72MN/A-0.40119IVVDInvivyd3.6086 of 5 stars$0.49-10.7%$7.89+1,515.0%-72.4%$58.42M$11.56M-0.28100News CoverageAADIAadi Bioscience2.1113 of 5 stars$2.37-1.7%$1.67-29.7%+1.7%$58.41M$25.07M-1.0640Short Interest ↓Positive NewsKRONKronos Bio3.5935 of 5 stars$0.95-2.6%$1.63+70.3%-35.6%$57.59M$9.86M-0.69100IMMXImmix Biopharma2.7665 of 5 stars$2.05+0.5%$7.00+241.5%-73.2%$56.39MN/A-2.479Short Interest ↑News CoverageGap Down Related Companies and Tools Related Companies BeyondSpring Alternatives VolitionRx Alternatives Atara Biotherapeutics Alternatives Connect Biopharma Alternatives Spero Therapeutics Alternatives Mural Oncology Alternatives Invivyd Alternatives Aadi Bioscience Alternatives Kronos Bio Alternatives Immix Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NERV) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NERV Stock Alerts